|
 The Florida House members, led by Speaker-designate Richard Corcoran
and Democratic leader-designate Janet Cruz, have written to the U.S.
Department of Health and Human Services, and the U.S. Food and Drug
Administration (FDA), seeking permission for the state and local
governments to use the GM mosquito, the company said.
FDA said in an email to Reuters that it had received the letter and
will respond directly to the Florida coalition, without specifying a
timeframe for it.
No vaccine or treatment has been approved for Zika.
The virus, first detected in Brazil last year, has rapidly spread
across the Americas and parts of Asia.
In recent weeks, U.S. authorities determined that local mosquitoes
were transmitting Zika in an area of south Florida. The U.S.
territory of Puerto Rico has also experienced a widespread outbreak.
U.S. health regulators cleared the way last month for a trial in Key
Haven, Florida to assess the effectiveness of Intrexon's GM
mosquitoes to reduce levels of the aedes aegypti mosquito
population, which is known to carry Zika, dengue and chikungunya.
There is vote scheduled in November seeking community approval for
the trial, as the use of Intrexon's mosquitoes have raised concerns
among the locals about its safety.
In the letter, the politicians said that delaying Florida's access
to Intrexon's technology posed "an unnecessary health risk" to the
people of Florida, the company said.
The mosquitoes are genetically altered so their offspring die before
they can reproduce.
[to top of second column] |
Trials in Brazil, Panama and the Cayman Islands have shown that the
GM mosquitoes can reduce localized Aedes aegypti populations by more
than 90 percent. (http://bit.ly/1McvLMg)
The GM mosquito strain is made by Oxitec, an Oxford University
spin-off company that is now a UK subsidiary of U.S.-based Intrexon.
While most people experience mild symptoms, Zika infections in
pregnant women have been shown to cause microcephaly, a severe birth
defect in which the head and brain are undersized. In adults, it can
cause a rare neurological syndrome called Guillain-Barre.
(Reporting by Natalie Grover in Bengaluru; Editing by Ted Kerr,
Saumyadeb Chakrabarty and Sunil Nair)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
